Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:trastuzumab
|
| gptkbp:activities |
HE R2 receptor blockade
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:1998
gptkb:FDA |
| gptkbp:associated_with |
improved survival rates
|
| gptkbp:can_be_used_with |
chemotherapy
hormonal therapy aromatase inhibitors |
| gptkbp:clinical_trial |
gptkb:healthcare_organization
Phase III esophageal cancer metastatic breast cancer early-stage breast cancer |
| gptkbp:contraindication |
history of hypersensitivity to trastuzumab
|
| gptkbp:developed_by |
gptkb:Genentech
|
| https://www.w3.org/2000/01/rdf-schema#label |
trastuzumab-anns
|
| gptkbp:indication |
HE R2-positive breast cancer
|
| gptkbp:interacts_with |
gptkb:docetaxel
gptkb:paclitaxel gptkb:pertuzumab gptkb:capecitabine |
| gptkbp:is_available_on |
solution for infusion
lyophilized powder |
| gptkbp:is_monitored_by |
left ventricular function
|
| gptkbp:is_used_for |
treatment of breast cancer
|
| gptkbp:lifespan |
approximately 5-7 days
|
| gptkbp:manager |
subcutaneous
|
| gptkbp:marketed_as |
gptkb:Herceptin
|
| gptkbp:microtransactions |
gptkb:trastuzumab
|
| gptkbp:pharmacokinetics |
antibody-dependent cellular cytotoxicity
complement-dependent cytotoxicity biphasic elimination |
| gptkbp:produced_by |
Chinese hamster ovary cells
|
| gptkbp:research_areas |
combination therapies
cancer immunotherapy HE R2-targeted therapies |
| gptkbp:side_effect |
gptkb:fandom
fatigue headache muscle pain nausea fever diarrhea rash joint pain chills thrombocytopenia infusion reactions neutropenia cardiotoxicity |
| gptkbp:social_structure |
Ig G1 monoclonal antibody
|
| gptkbp:targets |
HE R2 protein
|
| gptkbp:used_in |
adjuvant therapy
neoadjuvant therapy |